Kodu・Aktsiate loetelu・Intellia Therapeutics Inc

Intellia Therapeutics Inc

Suletud

SektorTervishoid

11.95 6.89

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.85

Max

12.04

Põhinäitajad
By Trading Economics
Sissetulek	106M -96M
Müük	-8M 15M
Aktsiakasum	-0.81
Kasumimarginaal	-639.494
Töötajad	377
EBITDA	1.4M -94M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+60.39% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	4. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-145M 1.5B
Eelmine avamishind	5.06
Eelmine sulgemishind	11.95

Uudiste sentiment

By Acuity

10%

90%

6 / 340 Pingereas Healthcare

Intellia Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2026, 19:26 UTC

News

Correlated Moves

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

6. aug 2026, 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

4. aug 2026, 19:36 UTC

Correlated Moves

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

3. aug 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

31. juuli 2026, 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30. juuli 2026, 17:57 UTC

Correlated Moves

News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29. juuli 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28. juuli 2026, 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

27. juuli 2026, 23:46 UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

25. juuli 2026, 00:02 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

24. juuli 2026, 13:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

23. juuli 2026, 19:16 UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

22. juuli 2026, 23:56 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

21. juuli 2026, 22:46 UTC

Intellia Therapeutics Inc shares are lower in after-market trading amid a lack of specific company news. The stock remains below its 20-day moving average.

20. juuli 2026, 23:41 UTC

Correlated Moves

Intellia Therapeutics shares are higher in after-market trading, reflecting a positive shift amid broader market trends and correlated gains in Beam Therapeutics.

Võrdlus sarnastega

Hinnamuutus

Intellia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

60.39% tõus

12 kuu keskmine prognoos

Keskmine 19.15 USD 60.39%

Kõrge 49 USD

Madal 8 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Intellia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Intellia Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

6 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.